Active, not recruitingPHASE1, PHASE2NCT05834296

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alzamend Neuro, Inc.
Intervention
ALZN002 (autologous DCs pulsed with E22W mutant peptide).(biological)
Enrollment
30 enrolled
Eligibility
60-85 years · All sexes
Timeline
2023 – 2028

Study locations (1)

Collaborators

bioRASI, LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05834296 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials